@article{oai:shiga-med.repo.nii.ac.jp:00003284,
 author = {寺島, 智也 and 小川, 暢弘 and 樫, 美和子 and 岡野, 純子 and 前川, 聡 and 小島, 秀人 and 寺島, 智也 and Ogawa, Nobuhiro and Nakase, Yuki and Sato, Toshiyuki and Katagi, Miwako and Okano, Junko and MAEGAWA, Hiroshi and KOJIMA, Hideto},
 journal = {Molecular therapy. Nucleic acids},
 month = {Mar},
 note = {Astrocyte- and microglia-targeting peptides were identified and isolated using phage 
display technology. A series of procedures, including three cycles of both in vivo and 
in vitro biopanning, was performed separately in astrocytes and in M1 or M2 microglia,
yielding 50-58 phage plaques in each cell type. Analyses of the sequences of this 
collection identified one candidate homing peptide targeting astrocytes (AS1[C-LNSSQPS-C]) and two candidate homing peptides targeting microglia (MG1[C-HHSSSAR-C] and MG2[C-NTGSPYE-C]). To determine peptide specificity for the target cell in vitro, 
each peptide was synthesized and introduced into the primary cultures of astrocytes or
 microglia. Those peptides could bind to the target cells and be selectively taken up by 
the corresponding cell, namely, astrocytes, M1 microglia, or M2 microglia. To confirm 
cell-specific gene delivery to M1 microglia, the complexes between peptide MG1 and 
siRNA-interferon regulatory factor 5 were prepared and intrathecally injected into a 
mouse model of neuropathic pain. The complexes successfully suppressed hyperalgesia 
with high efficiency in this neuropathic pain model. Here, we describe a novel gene 
therapy for the treatment neuropathic pain, which has a high potential to be of clinical 
relevance. This strategy will ensure the targeted delivery of therapeutic genes while 
minimizing side effects to non-target tissues or cells., Journal Article},
 pages = {203--215},
 title = {Gene Therapy for Neuropathic Pain through siRNA-IRF5 Gene Delivery with Homing Peptides to Microglia.},
 volume = {11},
 year = {2018}
}